Microplate Dx Limited

Microplate Dx Limited is a UK-based startup that aims to revolutionize antibiotic susceptibility testing diagnostics. Founded in 2021, the company's mission is to improve the quality of life for patients by providing antimicrobial stewardship in a cost-effective manner. Their flagship platform diagnostic test enables rapid antibiotic susceptibility testing at the point-of-care, allowing clinicians to confidently select the most effective antibiotic for a patient's infection in just minutes, a vast improvement over the current 2-day standard. This breakthrough technology not only saves valuable time but also addresses the critical global health issue of antimicrobial resistance, ultimately saving lives. In September 2023, Microplate Dx Limited secured a significant £2.50M Seed Round investment from a group of noteworthy investors including SIS Ventures, Scottish Enterprise, Deepbridge Capital, Thairm Bio, and the University of Strathclyde. This injection of capital underlines the confidence that these prominent investors have in the potential of the company's innovative approach to combatting antimicrobial resistance. Microplate Dx Limited operates within the biotechnology and healthcare industries and is poised to make a substantial impact in the fight against antimicrobial resistance, setting the stage for future growth and success.